Approach and Methodology. ARS will study experimental culture conditions for the ARS-PICM-19 cell line, its derivative cell lines, or other pig epiblast-derived liver cell lines (as described under ARS patent #5,532,156, “Hepatocyte Cell Line Derived from the Epiblast of Pig Blastocysts”) so as to optimize their hepatocyte functions for use as an in-vitro liver model, for their use in an artificial liver device, and for their use in the in-vitro assay of metabolic, toxic, or carcinogenic responses. Specific project objectives are the following:
Appears in 4 contracts
Samples: Agriculture Research Agreement (Hepalife Technologies Inc), Department of Agriculture Research Agreement (Hepalife Technologies Inc), Department of Agriculture Research Agreement (Hepalife Technologies Inc)
